Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT01284569 Completed - Clinical trials for Rheumatoid Arthritis

Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients

Start date: March 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the ALX-0061, a Nanobody targeting the receptor for interleukin 6 (IL6R), is safe and effective after single or multiple administrations to patients with rheumatoid arthritis (RA). Patients will receive different single or multiple doses of either placebo or ALX-0061.

NCT ID: NCT01284283 Completed - Clinical trials for Rheumatoid Arthritis

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

STAR 2 PAS
Start date: November 2009
Phase: N/A
Study type: Interventional

This post-approval study is being conducted to examine the performance of the STAR Ankle under actual conditions of use.

NCT ID: NCT01283971 Terminated - Clinical trials for Rheumatoid Arthritis

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Start date: May 2011
Phase: Phase 4
Study type: Interventional

This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid arthritis. Patients, already treated with MTX at stable doses, will be randomized to receive either RoActemra/Actemra 8 mg/kg intravenously (IV) every 4 weeks or adalimumab 40 mg subcutaneous (SC) every 2 weeks. All patients will receive methotrexate (10-25 mg weekly) and folate (at least 5 mg weekly). The anticipated time on study treatment is 24 weeks.

NCT ID: NCT01283399 Completed - Clinical trials for Rheumatoid Arthritis

An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

Start date: August 2010
Phase: N/A
Study type: Observational

This observational study will assess the efficacy and safety of combination of rituximab (MabThera) and methotrexate in participants with active refractory rheumatoid arthritis (RA) who have failed to respond to a single course of anti-tumor necrosis factor (TNF) therapy in routine clinical practice. Data will be collected from participants for 12 months after the first dose of rituximab or a minimum of 6 months following a rituximab re-treatment course.

NCT ID: NCT01282528 Recruiting - Clinical trials for Rheumatoid Arthritis

Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis

ULTRA
Start date: September 2010
Phase: Phase 4
Study type: Interventional

To evaluate the predictive value of clinical, functional (HAQ), laboratory and US variables in relation to disease activity and radiographic outcome in patients with RA who start treatment with Remicade at 24 weeks.

NCT ID: NCT01282372 Completed - Clinical trials for Rheumatoid Arthritis

Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab

Start date: March 2011
Phase: N/A
Study type: Observational

Treatment with tumor necrosis factor (TNF) inhibitors, especially adalimumab, demonstrated an improvement in work productivity in participants with rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Limited data was available for the effect of adalimumab treatment on sleep in all three diseases (RA, PsA, and AS) and no data was available for the effect of adalimumab treatment on work productivity in PsA. This long term Health-Related Quality of Life (HRQL) observational study was conducted to evaluate the effect of treatment with adalimumab on work productivity and sleep disturbance in Greek participants with moderate to severe rheumatic diseases (RA, PsA, and AS).

NCT ID: NCT01282255 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to evaluate the change in disease activity following 12 weekly s.c. (under the skin) doses of NNC109-0012 compared to placebo in subjects with active Rheumatoid Arthritis (RA).

NCT ID: NCT01277328 Terminated - Clinical trials for Rheumatoid Arthritis

An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Start date: May 2010
Phase: N/A
Study type: Observational

This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.

NCT ID: NCT01274910 Recruiting - Clinical trials for Rheumatoid Arthritis

Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial

EFOPaKR-01
Start date: January 2011
Phase: N/A
Study type: Interventional

This is a single-center, prospective, randomized, double blind, placebo control study. The aim of this study is to assess the effect of fish oil capsules on pain intensity and postoperative analgesics consumption in patients after knee replacement surgery. The study population will be adult are referred for knee replacement surgery due to osteoarthritis of the knee.

NCT ID: NCT01274182 Completed - Clinical trials for Rheumatoid Arthritis

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.